TH1902 is a proprietary PDC, linked to docetaxel, a well-established and well-characterized cytotoxic agent. The U.S. Food and Drug Administration (FDA) recently granted fast track designation to TH1902 to be developed as a single agent for the treatment of all advanced solid tumors expressing sortilin that are refractory to standard therapy. TH1902 is the Company’s lead PDC stemming from Theratechnologies’ SORT1+ Technology™ in oncology.

TH1902 is currently being evaluated in a Phase 1 clinical trial, although patient recruitment has recently been voluntarily paused. The Company is currently analyzing the data obtained thus far from this trial and plans on filing an amended protocol with the FDA, subject to their approval, prior to pursuing the trial. 

Funda Meric-Bernstam, M.D., Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, is the Principal Investigator of the Phase 1 trial for TH1902.

The detailed Phase 1 study protocol is available at under the identifier number: NCT04706962.

TH1902 in Triple-Negative Breast Cancer